Navigation Links
Hemostemix Hosts Cell Therapy Industry Seminar
Date:10/30/2013

Toronto, Canada & Kyriat Weizmann, Israel (PRWEB) October 31, 2013

Hemostemix Ltd. and BioForum have announced a jointly-sponsored symposium entitled “Cell Therapy – an evolving industry” to be held November 4 at the Dan Hotel in Tel Aviv, Israel.

The event will feature invited speakers including Dr. Elmar Burchardt, Pfizer’s Vice President of Regenerative Medicine and cell therapy executives from Canada, United States, India, and Israel. The seminar will brief attendees on global industry trends, discuss optimal cell therapy product development, review the impact of CROs on clinical trial outcomes, present key elements of cellular product analytics, outline cell therapy business models, and engage in an open dialogue about the potential keys to cell therapy being a pillar of future healthcare.

“We are pleased to play a role in hosting an event which highlights the global cell therapy industry,” stated Hemostemix President and founder, Dr. Valentin Fulga. “With this seminar, and others planned, we want to facilitate an information-exchange and dialogue between investors, clinicians, and scientists that will promote a greater understanding of how cell therapies will shape the future of medicine.”

“Bioforum is excited to provide what it believes will be an important and useful seminar in this exciting new field of science and medicine,” stated Yehudith Wexler, Chairperson of Bioforum.
For more information about the seminar, click here.

This seminar is part of a series of presentations intended to introduce the company and its platform technology to a wide audience in the context of the cell therapy industry’s progress and maturation. This includes a recent keynote presentation (“Synergetic Cell Population – a powerful tool for autologous therapies”) delivered October 23rd in Orlando, FL and an upcoming presentation (“A peripheral blood-derived cellular population can be differentiated into neural like progenitor cells”) at the TERMIS-AM 2013 Conference to be held November 10-13in Atlanta, Georgia.

About Hemostemix Ltd

Hemostemix Ltd is a Canadian-Israeli company developing and commercializing innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. For more information see http://www.hemostemix.com.

About Bioforum

Established in 1998, Bioforum provides a wide range of services in the areas of Education and Training, Clinical Data, Regulatory Submissions and Clinical Supply (inPACK). Bioforum's strategic lines of business combine professional services, process optimization, technology and education. Bioforum maximizes their costumers’ benefits by providing cost effective outsourcing and consultation services for the pharmaceutical, medical and medical device industries. For more information about Bioforum, see http://www.bioforum.co.il.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11280279.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Hemostemix Announces Formation of Scientific Advisory Board
2. Hemostemix Announces US Patent Allowance
3. The Hemostemix Group of Companies Provides Corporate Strategy Update
4. Funding Tomorrow's Biomedical Research: California Healthcare Institute Hosts Pipeline for Life, July 15
5. DTx Hosts Webinar on New Intel® Haswell Platform
6. Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013
7. Industry Leader Linguamatics Hosts Record-breaking Spring Users Conference in Cambridge, UK
8. Cambridge College School of Management Program Hosts a Panel Discussion On Trends and Opportunities In Health Information Technology
9. San Diego State University Hosts Open House for Life Science Immersion Biotechnology Program
10. Ultra Light Startups Hosts Future Energy Investor Feedback Forum at MIT
11. Bayer CropScience Hosts Third Sustainability in Agriculture: A Bayer Executive Course
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , ... May 02, 2016 , ... ... its clients in mind, the fresh look and added functionality give the agricultural ... years have seen a dynamic shift in agriculture – from precision farming via ...
(Date:4/29/2016)... , ... April 30, 2016 , ... The MIT bioLogic ... design, the bioLogic team explored how bacterial properties can be applied to fabric and ... Natto bacteria, which move in response to humidity change. The team harvested Natto cells ...
(Date:4/29/2016)... , April 29, 2016 ... Transparency Market Research "Separation Systems for Commercial Biotechnology ... Trends, and Forecast 2015 - 2023", the separation ... US$ 10,665.5 Mn in 2014 and is projected ... 2015 to 2023 to reach US$ 19,227.8 Mn ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced today that the two-level ... sale in the United States. These components expand the capabilities of the system ... sales beginning in October of 2015, the company has seen significant sales growth in ...
Breaking Biology Technology:
(Date:3/9/2016)... YORK , March 9, 2016 This ... and future states of the RNA Sequencing (RNA Seq) ... segments such as instruments, tools and reagents, data analysis, ... Analyze various segments of the RNA-Sequencing market such as ... services Identify the main factors affecting each segment and ...
(Date:3/8/2016)... , March 8, 2016   Valencell ... technology, today announced it has secured $11M in ... GII Tech, a new venture fund being launched ... additional participation from existing investors TDF Ventures and ... funds to continue its triple-digit growth and accelerate ...
(Date:3/3/2016)... England and DE SOTO, Kansas ... , U.S.-based Stroke Detection Plus® to offer Oncimmune,s ... risk assessment and early detection of lung cancer ... large employers, unions and individuals. --> Early ... unions and individuals. --> Oncimmune, a leader ...
Breaking Biology News(10 mins):